Quantitative proteomics analysis of COVID-19 patients: Fetuin-A and tetranectin as potential modulators of innate immune responses

Alghanem, Bandar; Mansour, Fatmah A.; Shaibah, Hayat; Almuhalhil, Khawlah; Almourfi, Feras; Alamri, Hassan S.; Alajmi, Hala; Rashid, Mamoon; Alroqi, Fayhan; Jalouli, Maroua; Harrath, Abdel Halim; Boudjellal, Mohammad; Barhoumi, Tlili

doi:10.1016/j.heliyon.2023.e15224

Cited by 5 publications

(2 citation statements)

References 65 publications

(67 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PON1 and KNG1 levels significantly decreased in moderate patients compared to controls and showed a tendency towards a significant decrease in our severe COVID-19 patients compared to healthy controls. PON1 findings are consistent with previous studies that have demonstrated that decreased PON1 levels are associated with disease severity [26,33,45,46]. A tendency towards a significant increase in hemoglobin levels for the moderate group was observed.…”

Section: Discussionsupporting

confidence: 92%

Plasma Proteins Associated with COVID-19 Severity in Puerto Rico

Rosario-Rodríguez,

Cantres-Rosario,

Carrasquillo-Carrión

et al. 2024

IJMS

View full text Add to dashboard Cite

Viral strains, age, and host factors are associated with variable immune responses against SARS-CoV-2 and disease severity. Puerto Ricans have a genetic mixture of races: European, African, and Native American. We hypothesized that unique host proteins/pathways are associated with COVID-19 disease severity in Puerto Rico. Following IRB approval, a total of 95 unvaccinated men and women aged 21–71 years old were recruited in Puerto Rico from 2020–2021. Plasma samples were collected from COVID-19-positive subjects (n = 39) and COVID-19-negative individuals (n = 56) during acute disease. COVID-19-positive individuals were stratified based on symptomatology as follows: mild (n = 18), moderate (n = 13), and severe (n = 8). Quantitative proteomics was performed in plasma samples using tandem mass tag (TMT) labeling. Labeled peptides were subjected to LC/MS/MS and analyzed by Proteome Discoverer (version 2.5), Limma software (version 3.41.15), and Ingenuity Pathways Analysis (IPA, version 22.0.2). Cytokines were quantified using a human cytokine array. Proteomics analyses of severely affected COVID-19-positive individuals revealed 58 differentially expressed proteins. Cadherin-13, which participates in synaptogenesis, was downregulated in severe patients and validated by ELISA. Cytokine immunoassay showed that TNF-α levels decreased with disease severity. This study uncovers potential host predictors of COVID-19 severity and new avenues for treatment in Puerto Ricans.

show abstract

Section: Discussionsupporting

confidence: 92%

Plasma Proteins Associated with COVID-19 Severity in Puerto Rico

Rosario-Rodríguez,

Cantres-Rosario,

Carrasquillo-Carrión

et al. 2024

IJMS

View full text Add to dashboard Cite

show abstract

“…These results are consistent with the COVID-19 protein profiling results. AACT may be related to platelet reduction caused by COVID-19, whereas Fetuin-A, as a protective protein, can inhibit the release of early (TNF, IL-1, IL-6, and INF) and late (HMGB1) mediators by innate immune cells such as macrophages[39]. Therefore, further exploration of the role of AACT and Fetuin-A in the progression of COVID-19 in China would be highly meaningful.…”

mentioning

confidence: 99%

Plasma proteome analysis and validation of patients with community‐acquired pneumonia: A cohort study

Zhao,

Bian,

Shang

et al. 2024

Proteomics Clinical Apps

View full text Add to dashboard Cite

PurposeThis study aimed to investigate the diagnostic potential of plasma biomarkers of community‐acquired pneumonia (CAP) and their severity grading.Experimental designPlasma proteomes from cohort I (n = 32) with CAP were analyzed by data‐independent acquisition mass spectrometry (MS). MetaboAnalyst 5.0 was used to statistically evaluate significant differences in proteins from different samples, and demographic and clinical data were recorded for all enrolled patients. Cohort II (n = 80) was used to validate candidate biomarkers. Plasma protein levels were determined using quantitative enzyme‐linked immunosorbent assay (ELISA). Correlations were assessed using Pearson's correlation coefficient. A receiver operating characteristic curve was used to verify the association between the variables, CAP diagnosis, and prognosis.Results121 differentially expressed proteins (DEPs) were obtained between CAP and controls. These DEPs were mainly aggregated in pathways of phagosome(hsa04145) and complement and coagulation cascades (hsa04610). No significant differential proteins were detected in bacterial, viral, and mixed infection groups. The plasma levels of fetuin‐A, alpha‐1‐antichymotrypsin (AACT), α1‐acid glycoprotein (A1AG), and S100A8/S100A9 heterodimers detected by ELISA were consistent with those of MS. AACT, A1AG, S100A8/S100A9 heterodimer, and fetuin‐A can potentially be used as diagnostic predictors, and fetuin‐A and AACT are potential predictors of SCAP.Conclusions and clinical relevancePlasma protein profiling can successfully identify potential biomarkers for CAP diagnosis and disease severity assessment. These biomarkers should be further studied for their clinical application.

show abstract